Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2863-2874

  Schneider, Lina S ^a   Von Schwarzenberg, Karin ^a   Lehr, Thorsten ^b   Ulrich, Melanie ^a   Kubisch Dohmen, Rebekka ^a   Liebl, Johanna ^a   Trauner, Dirk ^a   Menche, Dirk ^c   Vollmar, Angelika M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ARCHAZOLID; DEFEROXAMINE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIFITHRIN ALPHA; PROTEIN P53; UNCLASSIFIED DRUG; VACUOLAR ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ARCHAZOLID A; ENZYME INHIBITOR; IRON; MACROLIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IRON METABOLISM; METABOLIC STRESS; MOUSE; NONHUMAN; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; IRON; MACROLIDES; MCF-7 CELLS; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, INBRED BALB C; THIAZOLES; TUMOR CELLS, CULTURED; VACUOLAR PROTON-TRANSLOCATING ATPASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942164064     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2097     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-35.
3. Sasse F, Steinmetz H, Höfle G, Reichenbach H. Archazolids, new cytotoxic macrolactones from archangium gephyra (Myxobacteria) production, isolation, physico-chemical and biological properties. J Antibiot 2003; 56: 520-5.
4. Bockelmann S, Menche D, Rudolph S, Bender T, Grond S, von Zezschwitz P, et al. Archazolid A binds to the equatorial region of the c-ring of the vacuolar H+-ATPase. J Biol Chem 2010; 285: 38304-14.
5. Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, et al. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem 2005; 6: 13.
6. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem 2012; 288: 1385-96.
7. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007; 8: 917-29.
8. Barar J, Omidi Y. Dysregulated pH in tumormicroenvironment checkmates cancer therapy. Bioimpacts 2013; 3: 149-62.
9. Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, et al. Targeting the actin cytoskeleton: selective antitumor action via trapping PKCe. Cell Death Dis 2014; 5: e1398.
10. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101.
11. Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L, et al. Indirubin derivative 6BIO suppresses metastasis. Cancer Res 2013; 73: 6004-12.
12. Wilson PM, LaBonte MJ, Russell J, Louie S, Ghobrial AA, Ladner RD. A novel fluorescence-basedassay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates. Nucleic Acids Res 2011; 39: e112.
13. Bliss CI The calculation of microbial assays. Bacteriol Rev 1956; 20: 243-58.
14. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992; 17: 119-23.
15. Ohta T, Numata M, Yagishita H, Futagami F, Tsukioka Y, Kitagawa H, et al. Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Br J Cancer 1996; 73: 1511-7.
16. Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, et al. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem 2009; 284: 16400-8.
17. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-39.
18. Petzoldt AG, Gleixner EM, Fumagalli A, Vaccari T, Simons M. Elevated expression of the V-ATPase C subunit triggers JNK-dependent cell invasion and overgrowth in a Drosophila epithelium. Dis Model Mech 2013; 6: 689-700.
19. Morimura T, Fujita K, Akita M, Nagashima M, Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int 2008; 24: 1087-94.
20. Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res 2012; 72: 5976-87.
21. Wu YC, Wu WKK, Li Y, Yu L, Li ZJ, Wong CCM, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 2009; 382: 451-6.
22. Nakashima S. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem 2003; 134: 359-64.
23. Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol 1998; 185: 324-30.
24. Richmond HG Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1959; 1: 947-9.
25. Greenberg G. Sarcoma after intramuscular iron injection. Br Med J 1976; 1: 1508-9.
26. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New Engl J Med 1988; 319: 1047-52.
27. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-37.
28. Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 2004; 40: 1418-22.
29. Law S. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol Rep 2014; 31: 1296-304.
30. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, et al. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res 1995; 1: 1259-65.
31. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 1986; 46: 1759-63.
32. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012; 1820: 291-317.
33. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 1983; 80: 2258-62.
34. Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986; 55: 663-700.
35. Kozik P, Hodson NA, Sahlender DA, Simecek N, Soromani C, Wu J, et al. A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase. Nat Cell Biol 2012; 15: 50-60.
36. Kobia F, Duchi S, Deflorian G, Vaccari T. Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling. Mol Oncol 2014; 8: 207-20.
37. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 2006; 12: 6876-83.
38. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13: 342-55.
39. Robbins E, Pederson T. Iron: its intracellular localization and possible role in cell division. Proc Natl Acad Sci U S A 1970; 66: 1244-51.
40. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science 1993; 260: 1773-7.
41. Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci 1992; 50: 2059-65.
42. Koc A, Wheeler LJ, Mathews CK, Merrill GF. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J Biol Chem 2003; 279: 223-30.
43. Osterman Golkar S, Czene S, Gokarakonda A, Haghdoost S. Intracellular deoxyribonucleotide pool imbalance and DNA damage in cells treated with hydroxyurea, an inhibitor of ribonucleotide reductase. Mutagenesis 2013; 28: 653-60.
44. Box VGS. The intercalation of DNA double helices with doxorubicin and nagalomycin. J Mol Graphics Model 2007; 26: 14-9.
45. Piret J-P, Mottet D, Raes M, Michiels C. Is HIF-1αa pro- or an anti-apoptotic protein? Biochem Pharmacol 2002; 64: 889-92.
46. Denko NC Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
47. Tuderman L, Myllyla R, Kivirikko KI. Mechanism of the prolyl hydroxylase reaction. 1. Role of co-substrates. Eur J Biochem 1977; 80: 341-8.
48. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2: e164.
49. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007; 26: 7741-8.
50. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22: 9030-40.
51. Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13: 217-36.
52. Lips J, Kaina B. DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts. Carcinogenesis 2001; 22: 579-85.